GIST Specialist for Beverly Crest, CA
Surgery removes the tumor. What happens over the following three years decides whether it stays gone. Joshua Ellenhorn, MD, FACS makes sure the adjuvant decision is made on all five inputs rather than by default.
- Risk grading calculated and stated explicitly
- Clinical Professor of Surgery, Cedars-Sinai Medical Center
- Mutation subtype established before therapy begins
- Fifteen to twenty minutes down to 3rd Street
Three Years Is Not an Arbitrary Number
For higher risk gastrointestinal stromal tumors, three years of imatinib after surgery is the standard. That figure exists because a randomised trial compared three years against one and found the longer course improved not only the time before recurrence but survival itself. It is one of the clearer results in sarcoma medicine.
What the same data implies is more interesting. Recurrences tend to cluster in the period after the drug stops rather than being spread evenly, which suggests imatinib is suppressing residual microscopic disease rather than eradicating it. That observation is what drives the ongoing question of whether five years, or longer, would be better still for the highest risk patients.
The decision is not simply a duration, though. It depends on five things: tumor size, site, mitotic index, mutation subtype, and whether the capsule ruptured. Miss any of them and the recommendation is being made blind. A patient with a PDGFRA D842V tumor put on standard imatinib will get the side effects and very little of the benefit. A patient with an exon 9 mutation on a standard dose may be underdosed. A patient whose tumor ruptured may need indefinite therapy rather than three years.
None of this is obscure. It requires the pathology to be complete and someone to actually apply it.
The Five Inputs to the Adjuvant Decision
Each of these should appear in your records. If any is missing, the duration is being chosen without it.
| Input | Where it comes from | How it changes the decision |
|---|---|---|
| Tumor size | Pathology of the resected specimen | Larger tumors carry higher recurrence risk and push toward treatment |
| Site | Operative findings and pathology | Non gastric tumors carry higher risk than gastric tumors of equal size |
| Mitotic index | Pathology, counted per 50 high power fields or 5 square millimetres | Together with size and site this produces the risk category that decides whether treatment is warranted at all |
| Mutation subtype | Molecular testing on the specimen | Exon 11 benefits clearly. Exon 9 needs higher dosing. D842V and SDH-deficient tumors benefit little, making standard imatinib largely side effects without gain |
| Capsule integrity | Operative report and pathology | Rupture means peritoneal seeding. Many specialists continue therapy indefinitely rather than stopping at three years |
Lower risk tumors generally need no adjuvant therapy. Treating them anyway exposes patients to three years of side effects for negligible benefit, which is as much a failure as undertreating.
Adherence Over Three Years Is the Real Challenge
Imatinib is generally well tolerated relative to conventional chemotherapy, which is a low bar. In practice most patients experience something: swelling around the eyes and ankles, fatigue, muscle cramps, nausea, rash, or changes in blood counts. Individually these are minor. Sustained across three years, they wear people down.
The consequence is that patients quietly stop, or take it intermittently, and do not mention it. That matters because the benefit demonstrated in the trials assumed people took the drug. A three year course taken half the time is not a three year course.
Most of these effects are manageable. Dose adjustment, timing relative to meals, attention to salt and fluid, and simple measures for cramps make a real difference, and a dose reduction that allows someone to continue is far better than a full dose they abandon. The essential thing is to raise it rather than absorb it silently, and to raise it with the oncologist prescribing rather than waiting for a scheduled review.
What the Recommendation Usually Looks Like
The same operation can be followed by three quite different plans, depending on the five inputs above.
No Adjuvant Therapy
A small gastric tumor with a low mitotic count and an intact capsule. Surveillance imaging at widening intervals with a defined endpoint, and no medication. This is a good outcome rather than an under-treatment.
Three Years of Imatinib
Larger tumors, non gastric sites, or high mitotic counts with a KIT exon 11 mutation. Three years at standard dose, with surveillance continuing past the end of treatment because recurrences cluster after stopping.
Indefinite or Alternative
A ruptured capsule frequently means continuing therapy without a planned stop. A D842V or SDH-deficient tumor means standard imatinib is the wrong drug, and the conversation moves to alternatives.
The Surgery That Precedes All of This
Recordings of real GIST resections narrated by the surgeon who performed them. Capsule integrity, visible in these, is one of the five inputs to everything above.
Laparoscopic Resection of a Gastric GIST
A gastric GIST removed through small incisions with the capsule kept intact, which keeps the adjuvant conversation straightforward.
Gastric GIST Resection: A Simplified Approach
A refined approach that shortens operating time and recovery.
Robotic Resection of a Duodenal GIST
Duodenal GIST removed robotically with the pancreas and bile duct preserved.
What Is My Risk Category?
The adjuvant recommendation follows from it. If nobody can tell you which category you are in, or what your mitotic index and mutation subtype are, the duration you have been given was not calculated from your tumor.
Certifications and Appointments
Two American Board of Surgery certifications, a Cedars-Sinai teaching appointment, and membership of the societies that publish the adjuvant guidance described above.
- American Board of Surgery, certified in General Surgery
- American Board of Surgery, certified in Colorectal Surgery
- California State Medical License
- Florida State Medical License
Joshua Ellenhorn, MD, FACS
Dr. Ellenhorn is a surgical oncologist and Clinical Professor of Surgery at Cedars-Sinai Medical Center, and a collaborative member of the Samuel Oschin Comprehensive Cancer Institute.
The adjuvant decision sits awkwardly between specialties, which is why it is worth a surgeon paying attention to it. The drug is prescribed by oncology, but four of the five inputs come from the operation and the specimen it produced. A surgeon who hands over a pathology report without ensuring the mitotic index was counted and the mutation tested has left the next decision to be made on incomplete information. Following that through is unglamorous and it changes outcomes.
He is certified by the American Board of Surgery in General Surgery and in Colorectal Surgery, a Fellow of the American College of Surgeons, and a member of the Society of Surgical Oncology and the American Society of Clinical Oncology. He practises with the Surgery Group of Los Angeles.
Questions Before Starting or Stopping Imatinib
Take these to whoever is prescribing. All are answerable from your existing pathology.
- What is my risk category, and from which three numbers?
- What mutation subtype do I have?
- Is standard dosing appropriate for that subtype?
- Was the capsule intact at surgery?
- How long is the planned course, and why that duration?
- What happens to my surveillance when the drug stops?
- What side effects should prompt me to call rather than endure?
- Would a dose reduction be preferable to stopping if I struggle?
What Patients Say
Reviews left by patients treated by Dr. Ellenhorn at the Surgery Group of Los Angeles.
★★★★★Very kind stuff, great service. Dr Joshua Ellenhorn is a very calm doctor who takes time with his patient.
Anita Lukacevic
★★★★★The staff at the Surgery Group of Los Angeles are wonderful. They are kind, very attentive, the office is clean and I did not have to wait long at all. I cannot say enough great things about Dr. Ellenhorn. He is an excellent surgeon who is highly skilled and very knowledgeable. I cannot thank him enough for all he has done for my family and I.
Erika Frank
Down From Beverly Crest
Coldwater Canyon or Beverly Glen down to Sunset, east through Beverly Hills, then south on Doheny or La Cienega to 3rd Street. Fifteen to twenty minutes in ordinary conditions, longer during the canyon peaks in the morning and late afternoon.
The office is in the medical plaza attached to Cedars-Sinai Medical Center, where medical oncology sits in the same institution as the surgical practice. For the decision described on this page that adjacency is the substance rather than a convenience, because the surgeon and the prescriber are working from the same record rather than corresponding about it.
Patients travelling from outside the region, including Arizona and Nevada, can have pathology and imaging reviewed remotely.
8635 W 3rd St, Suite 880W
Los Angeles, CA 90048
Monday to Saturday, 11:00am to 8:00pm
Closed Sunday
Frequently Asked Questions
How long should I take imatinib after surgery?
Why three years rather than one, or five?
Does everyone with a high risk tumor benefit?
What happens when I stop?
My tumor ruptured. Does that change the duration?
The side effects are difficult. Can I reduce the dose?
How far is your office from Beverly Crest?
Who decides the duration, my surgeon or my oncologist?
Three Years, None, or Indefinitely. It Depends on Five Things.
If you have been given an adjuvant duration without being told your risk category and mutation subtype, it is worth having the pathology reviewed before you commit to years of medication.
